- In October 2026, Aptar Pharma announced a collaboration with Stevanato Group to generate system level data on EZ-fill Nexa and Alba glass syringe platforms combined with Aptar Pharma plungers and needle shields for sensitive biologics and other injectable therapies.
- The partnership focuses on fully assembled system testing, giving drug developers earlier evidence on container closure integrity, break loose and extrusion forces, and other USP linked parameters that directly affect development timelines and technical risk.
- We will now assess how Stevanato Group’s system level testing collaboration with Aptar Pharma could influence the existing investment narrative.
Expand your watchlist with other packaging and drug delivery specialists by scanning our curated set of list of solid balance sheet and fundamentals (23 results) together with Stevanato Group.
Stevanato Group Investment Narrative Recap
To own Stevanato Group, you need to believe that higher value syringes, cartridges and devices for biologics and GLP 1 products can steadily become a larger share of activity, while new sites like Fishers and Latina move toward the efficiency targets management has outlined. The Aptar Pharma collaboration fits this view by reinforcing Stevanato Group’s role in complex biologic delivery systems rather than reshaping it.
The near term swing factor still looks tied to execution on capacity ramps, mix toward Nexa and Alba formats, and whether cost inflation and tax changes eat into the margin improvement that many investors are watching. The biggest risk remains pressure on biologics and GLP 1 related contracts or pricing, and the Aptar work does not materially change that exposure in the short run.
Among recent developments, the most relevant backdrop for this Aptar Pharma agreement is the ongoing push into high value Nexa and Alba syringes and EZ fill formats, now reported at 45% to 47% of revenue. That mix shift is central because it links directly to the higher margin profile that analysts and shareholders are already focused on.
The new system level testing data around sensitive biologics fits alongside efforts to scale cartridge and syringe capacity at Fishers and Latina and to optimize the Engineering segment that supports forming, sterilization and inspection. For you, the key question is whether these types of collaborations help Stevanato Group fill those premium lines more efficiently while keeping technical and regulatory risk controlled for customers.
Stevanato Group's current analyst narrative points to revenue of €1.6b and earnings of €257.3m by 2029, based on assumed yearly revenue growth of 9.3% and an earnings increase of about €122.7m from €134.6m today.
Uncover how Stevanato Group's fair value indicates a 21% potential upside to its current price before the discount to Stevanato Group closes.
Exploring Other Perspectives
Some of the most optimistic analysts frame the bigger swing factor for Stevanato Group as cartridge and device upside rather than just biologics demand risk. Before this Aptar Pharma news, they were sketching out earnings of about €285.8 million on €1.6b of revenue by 2029. You can compare that to the more cautious estimates and decide which storyline might adjust most as system level data from this partnership feeds into future forecasts.
Explore 3 other Stevanato Group fair value estimates, including one that suggests as much as 47% upside from the current price!
The Verdict Is Yours
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Stevanato Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Stevanato Group. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Stevanato Group's overall financial health at a glance.
Looking for more ideas beyond Stevanato Group?
If you want to broaden your watchlist around Stevanato Group and compare it with other potential opportunities, the Simply Wall St Screener can help you quickly sort through different types of businesses based on the traits you care about most.
- For investors who care about balance sheet strength and fundamentals first, start with this curated list of solid balance sheet and fundamentals (23 results) and see which companies match your quality threshold.
- If you want to focus on quality that the market may not be fully pricing, filter for potential mispriced opportunities using our list of 30 high quality undervalued stocks.
- Those who prefer a steadier ride can concentrate on stability with a focus on risk controls by scanning through 30 resilient stocks with low risk scores and comparing those profiles to Stevanato Group.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com